Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) have earned an average recommendation of “Moderate Buy” from the eight analysts that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $62.25.

CLDX has been the topic of several research analyst reports. Citigroup began coverage on shares of Celldex Therapeutics in a research note on Monday, October 7th. They issued a “buy” rating and a $70.00 price target on the stock. The Goldman Sachs Group assumed coverage on Celldex Therapeutics in a research report on Monday, September 30th. They issued a “neutral” rating and a $45.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of Celldex Therapeutics in a report on Thursday, December 19th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $67.00 price objective on shares of Celldex Therapeutics in a report on Thursday, January 2nd.

Insiders Place Their Bets

In other news, CEO Anthony S. Marucci bought 11,500 shares of Celldex Therapeutics stock in a transaction on Monday, November 11th. The stock was acquired at an average cost of $26.82 per share, for a total transaction of $308,430.00. Following the completion of the acquisition, the chief executive officer now owns 40,284 shares of the company’s stock, valued at $1,080,416.88. This trade represents a 39.95 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. 3.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Celldex Therapeutics

Several institutional investors have recently bought and sold shares of the company. Novo Holdings A S raised its holdings in shares of Celldex Therapeutics by 13.4% in the third quarter. Novo Holdings A S now owns 963,663 shares of the biopharmaceutical company’s stock worth $32,755,000 after buying an additional 113,663 shares during the last quarter. Jennison Associates LLC raised its holdings in Celldex Therapeutics by 32.0% in the 3rd quarter. Jennison Associates LLC now owns 1,324,410 shares of the biopharmaceutical company’s stock worth $45,017,000 after purchasing an additional 321,325 shares during the period. Point72 Asset Management L.P. lifted its position in shares of Celldex Therapeutics by 51.0% during the 2nd quarter. Point72 Asset Management L.P. now owns 1,937,991 shares of the biopharmaceutical company’s stock valued at $71,725,000 after buying an additional 654,194 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in Celldex Therapeutics by 293.2% during the third quarter. BNP Paribas Financial Markets now owns 28,181 shares of the biopharmaceutical company’s stock valued at $958,000 after purchasing an additional 21,013 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. boosted its holdings in Celldex Therapeutics by 47.5% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 845,560 shares of the biopharmaceutical company’s stock worth $31,294,000 after buying an additional 272,389 shares during the last quarter.

Celldex Therapeutics Stock Performance

Shares of Celldex Therapeutics stock opened at $24.02 on Wednesday. The company has a fifty day moving average of $25.64 and a 200 day moving average of $31.45. The company has a market capitalization of $1.59 billion, a P/E ratio of -9.35 and a beta of 1.62. Celldex Therapeutics has a fifty-two week low of $22.17 and a fifty-two week high of $53.18.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.